Compare ICFI & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICFI | MNKD |
|---|---|---|
| Founded | 1969 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2006 | 2004 |
| Metric | ICFI | MNKD |
|---|---|---|
| Price | $89.73 | $4.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $99.25 | $8.69 |
| AVG Volume (30 Days) | 207.7K | ★ 4.8M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.61 | N/A |
| Revenue | ★ $1,229,162,000.00 | $348,966,000.00 |
| Revenue This Year | $4.12 | $35.81 |
| Revenue Next Year | $5.33 | $11.89 |
| P/E Ratio | $34.13 | ★ N/A |
| Revenue Growth | 3.72 | ★ 22.23 |
| 52 Week Low | $58.83 | $2.23 |
| 52 Week High | $101.50 | $6.51 |
| Indicator | ICFI | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 60.23 | 56.27 |
| Support Level | $84.28 | $3.74 |
| Resistance Level | $89.91 | $4.55 |
| Average True Range (ATR) | 3.34 | 0.21 |
| MACD | -0.31 | 0.04 |
| Stochastic Oscillator | 53.91 | 77.92 |
ICF International Inc provides professional services and technology-based solutions, including management, technology and policy consulting and implementation services, to government and commercial clients in the U.S. and internationally. Its government clients include U.S. federal agencies, state and local governments and international governments, as well as commercial clients inside and outside the U.S. It supports clients in Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs; and Security and Other Civilian and Commercial markets. The company delivers services across the life cycle of a policy, program or project through Advisory Services, Program Implementation, Analytics Services, Digital Services and Engagement Services.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.